Midlands & Wales Advanced Therapy Treatment Centre (MW-ATTC)

ATMP可以是细胞疗法，也可以是基因疗法，在治疗目前无法治愈的疾病方面显示出巨大的潜力。这些疾病包括关节炎、肝病、几种癌症和糖尿病溃疡。ATMP才刚刚开始上市，英国发挥着主导作用。然而，即使新的ATMP疗法被开发并被证明有效，在向患者推广方面也存在**重大挑战**。造成这种情况的原因包括：运输活的产品很复杂，而且大多数NHS医院对这类产品不熟悉。该项目的负责人是伯明翰生物医学研究中心，这是一个全国性的卓越中心。威尔士政府还在细胞治疗方面进行了重大投资，并支持威尔士国民健康保险制度作为该项目的联合牵头单位。我们是一支由实业家、临床医生、学者和计算机系统专家**拥有在这个项目中取得成功所需的所有技能。我们的团队**覆盖了英格兰中部和威尔士**，使我们能够接触到主要的教学医院和近1500万人，为细胞疗法的成功提供了一个独特的机会。我们将：-建立一个医院网络，其医务人员接受过接收和管理ATMP的培训。-建立无缝的供应链，确保在从生产实验室转移到床边的过程中，“活的药物”保持健康和有效。-建立IT系统来管理端到端的过程。-使用真实的ATMP验证这一新的基础设施--提供一项计划，利用这一基础设施加快临床试验中ATMP的测试。-建立协议，以测试**新ATMP的成本是否与其临床有效性相符。**MW-ATTC的好处是：(A)具有挑战性的疾病患者将获得突破性药物；(B)ATMP公司将进入临床主流和市场；(C)对这一重要行业部门的投资将增加，因为我们证明英国是ATMP研发的绝佳地点。MW-ATTC将成为英国三个先进治疗中心之一，为患者和ATMP创新者共同工作，以巩固英国作为这一重要领域世界领导者的地位。“

"ATMPs, which can be _cell or gene therapies_, show great potential in treating patients with conditions that cannot be cured with current treatments. These include arthritis, liver disease, several types of cancer, and diabetic ulcers.ATMPs are just beginning to be available, with the UK playing a leading role. However, even when new ATMP therapies are developed and shown to be effective, there are **major challenges in rolling them out to patients**. The reasons for this include: complexities in transporting a 'living' product, and lack of familiarity with such products in most NHS hospitals.The project lead is the Birmingham Biomedical Research Centre, a national centre of excellence. The Welsh government has also made a major investment in cell therapy and is supportive of NHS Wales as the joint-lead on this project. We are a **team of industrialists, clinicians, academics and computer system experts** who have all the necessary skills to succeed in this project.Our group **covers the Midlands and Wales** giving us access to major teaching hospitals and almost 15 million people providing a unique opportunity to set cell therapy up to succeed.We will:-Set up a network of hospitals with medical staff trained to receive and administer ATMPs.-Build seamless supply chains that ensure that 'living medicines' remain healthy and effective as they are moved from the production laboratory to the bedside.-Put in place the IT systems to manage the end-to-end process.-Validate this new infrastructure using real ATMPs-Deliver a programme that uses this infrastructure to speed up the testing of ATMPs in clinical trials.-Set-up protocols to test whether the **cost of a new ATMP is justified by its clinical effectiveness.**The benefits of MW-ATTC are (a) Patients with challenging illnesses will get access to breakthrough medicines; (b) ATMP companies will get access to the clinical mainstream and market; (c) Investment in this important industry sector will increase, as we demonstrate that the UK is an excellent location for ATMP R&D. MW-ATTC will be one of three Advanced Therapy Treatment Centres in the UK, working together for patients and ATMP innovators, to reinforce the UK's position as a world leader in this important field."